Cargando…
CD44 Variant 9 Serves as a Poor Prognostic Marker in Early Gastric Cancer, But Not in Advanced Gastric Cancer
PURPOSE: The present study is to investigate the significance of CD44 variant 9 (CD44v9) expression as a biomarker in primary gastric cancer. MATERIALS AND METHODS: With various gastric tissues, we performed immunohistochemical staining for CD44v9. RESULTS: The positive expression rates for CD44v9 i...
Autores principales: | Go, Se-Il, Ko, Gyung Hyuck, Lee, Won Sup, Kim, Rock Bum, Lee, Jeong-Hee, Jeong, Sang-Ho, Lee, Young-Joon, Hong, Soon Chan, Ha, Woo Song |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Cancer Association
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720095/ https://www.ncbi.nlm.nih.gov/pubmed/25779358 http://dx.doi.org/10.4143/crt.2014.227 |
Ejemplares similares
-
Cyclin D1 Serves as a Poor Prognostic Biomarker in Stage I Gastric Cancer
por: Go, Se-Il, et al.
Publicado: (2022) -
The Use of CD44 Variant 9 and Ki-67 Combination Can Predicts Prognosis Better Than Their Single Use in Early Gastric Cancer
por: Go, Se-Il, et al.
Publicado: (2019) -
Prognostic impact of Ki-67 in patients with gastric cancer—the importance of depth of invasion and histologic differentiation
por: Ko, Gyung Hyuck, et al.
Publicado: (2017) -
D-Dimer Can Serve as a Prognostic and Predictive Biomarker for Metastatic Gastric Cancer Treated by Chemotherapy
por: Go, Se-Il, et al.
Publicado: (2015) -
PRDX4 overexpression is associated with poor prognosis in gastric cancer
por: Park, Sun Yi, et al.
Publicado: (2020)